Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim

Jeungwoon Hong, Byoungju Lee, Kwanyub Kang, Seung Hoon Lee, Jaehwan Ryu, Gangsoo Jung, Jaetaek Oh, Eui Cheol Jo, Chan Wha Kim

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


We describe the characterisation of a novel monoPEGylated recombinant human granulocyte colony-stimulating factor analogue, pegteograstim (Neulapeg), prepared by site-specific 20 kDa maleimide-PEG conjugation. An additional cysteine was inserted between Gly136 and Ala137 of filgrastim (methionyl human granulocyte colony-stimulating factor) for site-specific PEGylation, and Cys18 of filgrastim was replaced with Ser18 to prevent unwanted PEGylation. Pegteograstim was produced by Escherichia coli and purified by cation exchange chromatography, and its structural, physicochemical, biological and immunological properties were investigated. Male Sprague-Dawley rats were administered pegteograstim (100 μg/kg) and the pharmacokinetics and pharmacodynamics compared with those of filgrastim. The results of long-term stability testing of pegteograstim revealed no significant change in its quality attributes at 2–8 °C for 36 months. In addition, pegteograstim was stable under the accelerated conditions (25 ± 2 °C, RH of 60 ± 5%) for 6 months. The site-specific monoPEGylated pegteograstim is a highly pure, stable and novel drug for long-lasting treatment of chemotherapy-induced neutropenia.

Original languageEnglish
Pages (from-to)54-61
Number of pages8
Publication statusPublished - 2018 Jan

Bibliographical note

Funding Information:
This work was supported by the Green Cross Corporation .

Publisher Copyright:
© 2017


  • Filgrastim
  • Maleimide-PEG
  • Neutropenia
  • PEGylation
  • Pegteograstim
  • rhG-CSF analogue

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • General Immunology and Microbiology
  • Pharmacology


Dive into the research topics of 'Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim'. Together they form a unique fingerprint.

Cite this